Literature DB >> 18006668

An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma.

K Miller1, J H Price, S P Dobbs, R H McClelland, K Kennedy, W G McCluggage.   

Abstract

AIMS: Traditional management of advanced ovarian carcinoma is surgical debulking followed by chemotherapy; however, there is an increasing tendency for neoadjuvant chemotherapy followed by surgery. The morphology of ovarian carcinoma following chemotherapy often differs markedly from native tumour. This study aimed to compare the immunophenotype of post-chemotherapy ovarian carcinomas with that of untreated tumour.
METHODS: Post-chemotherapy ovarian carcinomas (n = 16) were stained with a range of antibodies. In six cases, pre-chemotherapy core biopsies were also stained; all were high-grade serous carcinomas. Antibodies used in the study were CK7, CA125, WT1, ER, PR, p53, p16, p63 and MIB1.
RESULTS: In eight post-treatment cases, there was minimal or no morphological response to chemotherapy, and in eight there was a significant response (in two additional cases, no residual tumour was identified). All pre-chemotherapy biopsies showed diffuse positivity of the tumour cells with CK7, CA125 and WT1. ER, p53 and p16 were diffusely positive in five, four and three cases respectively. One case was focally PR positive, and all were p63 negative. MIB1 staining was high; all but one case exhibited a proliferation index of >60%. Post-chemotherapy tumours exhibited a similar immunophenotype: diffuse positivity with CK7 in all cases and with CA125, WT1, ER, p53 and p16 in the majority, an immunophenotype in keeping with a serous carcinoma. All were negative with p63, and all but two with PR. The MIB1 proliferation index was lower in those cases exhibiting a significant morphological response, and p53 was less likely to be positive in cases with minimal or no response.
CONCLUSIONS: The immunophenotype of post-chemotherapy ovarian carcinomas is very similar to that of native untreated tumours, illustrating that CK7, CA125, WT1, ER, p53 and p16 may be of value in identifying residual tumour cells and in subtyping the neoplasm if a pre-chemotherapy biopsy has not been obtained.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006668     DOI: 10.1136/jcp.2007.053793

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma.

Authors:  Asha Mahadevappa; Shruthi Mysore Krishna; Manjunath Gubbanna Vimala
Journal:  J Clin Diagn Res       Date:  2017-02-01

2.  MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Authors:  Eun Young Kang; Joshua Millstein; Gordana Popovic; Nicola S Meagher; Adelyn Bolithon; Aline Talhouk; Derek S Chiu; Michael S Anglesio; Betty Leung; Katrina Tang; Neil Lambie; Marina Pavanello; Annalyn Da-Anoy; Diether Lambrechts; Liselore Loverix; Siel Olbrecht; Christiani Bisinotto; Jesus Garcia-Donas; Sergio Ruiz-Llorente; Monica Yagüe-Fernandez; Robert P Edwards; Esther Elishaev; Alexander Olawaiye; Sarah Taylor; Beyhan Ataseven; Andreas du Bois; Philipp Harter; Jenny Lester; Claus K Høgdall; Sebastian M Armasu; Yajue Huang; Robert A Vierkant; Chen Wang; Stacey J Winham; Sabine Heublein; Felix K F Kommoss; Daniel W Cramer; Naoko Sasamoto; Lilian van-Wagensveld; Maria Lycke; Constantina Mateoiu; Janine Joseph; Malcolm C Pike; Kunle Odunsi; Chiu-Chen Tseng; Celeste L Pearce; Sanela Bilic; Thomas P Conrads; Arndt Hartmann; Alexander Hein; Michael E Jones; Yee Leung; Matthias W Beckmann; Matthias Ruebner; Minouk J Schoemaker; Kathryn L Terry; Mona A El-Bahrawy; Penny Coulson; John L Etter; Katherine LaVigne-Mager; Juergen Andress; Marcel Grube; Anna Fischer; Nina Neudeck; Greg Robertson; Rhonda Farrell; Ellen Barlow; Carmel Quinn; Anusha Hettiaratchi; Yovanni Casablanca; Ramona Erber; Colin J R Stewart; Adeline Tan; Yu Yu; Jessica Boros; Alison H Brand; Paul R Harnett; Catherine J Kennedy; Nikilyn Nevins; Terry Morgan; Peter A Fasching; Ignace Vergote; Anthony J Swerdlow; Francisco J Candido Dos Reis; G Larry Maxwell; Susan L Neuhausen; Arantzazu Barquin-Garcia; Francesmary Modugno; Kirsten B Moysich; Philip J Crowe; Akira Hirasawa; Florian Heitz; Beth Y Karlan; Ellen L Goode; Peter Sinn; Hugo M Horlings; Estrid Høgdall; Karin Sundfeldt; Stefan Kommoss; Annette Staebler; Anna H Wu; Paul A Cohen; Anna DeFazio; Cheng-Han Lee; Helen Steed; Nhu D Le; Simon A Gayther; Kate Lawrenson; Paul D P Pharoah; Gottfried Konecny; Linda S Cook; Susan J Ramus; Linda E Kelemen; Martin Köbel
Journal:  Virchows Arch       Date:  2021-11-15       Impact factor: 4.535

3.  Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.

Authors:  Damanzoopinder Samrao; Dan Wang; Faith Ough; Yvonne G Lin; Song Liu; Teodulo Menesses; Annie Yessaian; Nicole Turner; Tanja Pejovic; Paulette Mhawech-Fauceglia
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

4.  Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer.

Authors:  Marianne J Rutten; Gabe S Sonke; Anneke M Westermann; Willemien J van Driel; Johannes W Trum; Gemma G Kenter; Marrije R Buist
Journal:  Obstet Gynecol Int       Date:  2015-05-27

5.  Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer.

Authors:  Tiyasha H Ayub; Mignon-Denise Keyver-Paik; Manuel Debald; Babak Rostamzadeh; Thore Thiesler; Lars Schröder; Winfried Barchet; Alina Abramian; Christina Kaiser; Glen Kristiansen; Walther Kuhn; Kirsten Kübler
Journal:  Oncotarget       Date:  2015-06-30

6.  Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.

Authors:  Binny Khandakar; Sandeep R Mathur; Lalit Kumar; Sunesh Kumar; Siddhartha Datta Gupta; Venkateswaran K Iyer; M Kalaivani
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

7.  Postchemotherapy histopathological evaluation of ovarian carcinoma: a 40-case study.

Authors:  Kanwardeep Kaur Tiwana; Sarita Nibhoria; Manmeet Kaur; Tanvi Monga; Ratika Gupta
Journal:  Chemother Res Pract       Date:  2015-01-21

8.  Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models.

Authors:  Tony Yeung; Oliver Fung; Mikhail Bashkurov; Arian Khandani; Omar Subedar; Alexandra Wudwud; Patricia Shaw; Blaise Clarke; John Bartlett; Robert Rottapel; Andras Kapus
Journal:  Oncotarget       Date:  2019-11-19

9.  Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update.

Authors:  Frediano Inzani; Damiano Arciuolo; Giuseppe Angelico; Angela Santoro; Antonio Travaglino; Nicoletta D'Alessandris; Giulia Scaglione; Michele Valente; Federica Cianfrini; Antonio Raffone; Gian Franco Zannoni
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.